| Ytd | -75.83% | |
| 1y | -76.65% |
| Open | 1.31 | Prev Close | 1.29 | Low | 1.28 | High | 1.35 | Mkt Cap | 8.58M |
| Vol | 21.62K | Avg Vol | 406.70K | EPS | -1.31 | P/E | N/A | Forward P/E | -25.38 |
| Beta | 1.28 | Short Ratio | 0.19 | Inst. Own | 4.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.71 | 200-d Avg | 3.62 | 1yr Est | 2.00 |
XCUR News
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after
Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company") today announced that it exp
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market sess
Shares of Aehr Test Systems (NASDAQ: AEHR) jumped 29.6% to $93.30 in pre-market trading. Aehr Test
Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session.
WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
Exicure, Inc. (NASDAQ:XCUR) (the "Company") today announced that it received a notification
WILMINGTON, Del. , June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the "Company") to
Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and conf
Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.29) per share. This is a 159.18 percent decre
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has
Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hema
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-st
Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.22) per share. This is a 93.51 percent increa
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”)
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”)
On February 11, 2026, the board of directors (the "Board") of Exicure, Inc. (the "Compan
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection,
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-sta
Exicure, Inc. (NASDAQ: XCUR - Get Free Report) was the recipient of a significant decline in short i
Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 millio
Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collecti
Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-
XCUR: 176% | Exicure shares are trading higher after the company announced results from its complete
Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hema
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-sta
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”)
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-sta